Source 1primary paper2026MED
Toolkit/CAR-NKT cells
CAR-NKT cells
Also known as: CAR-NKT
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Usefulness & Problems
Why this is useful
CAR-NKT cells are NKT cells engineered with chimeric antigen receptors. The abstract names them as one of the CAR modalities discussed in the review.; expanded CAR modality coverage
Source:
CAR-NKT cells are NKT cells engineered with chimeric antigen receptors. The abstract names them as one of the CAR modalities discussed in the review.
Source:
expanded CAR modality coverage
Problem solved
They provide another engineered immune-cell format within the CAR therapy toolkit.; extends CAR engineering to NKT-cell-based therapy
Source:
They provide another engineered immune-cell format within the CAR therapy toolkit.
Source:
extends CAR engineering to NKT-cell-based therapy
Problem links
extends CAR engineering to NKT-cell-based therapy
LiteratureThey provide another engineered immune-cell format within the CAR therapy toolkit.
Source:
They provide another engineered immune-cell format within the CAR therapy toolkit.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
Operational role: actuator. Implementation mode: genetically encoded. Cofactor status: cofactor requirement unknown.
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
CAR-NK approaches are being used to target HIV.
CAR-NK approaches targeting HIV
CAR-Tregs enhance transplant tolerance.
CAR-Tregs enhancing transplant tolerance
CD19/BCMA-targeted CAR-T cells have achieved long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression.
CD19/BCMA-targeted CAR-T cells achieving long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression
Senolytic CARs reduce tissue fibrosis.
senolytic CARs reducing tissue fibrosis
Logic-gated CARs are highlighted as an innovation in next-generation CAR therapy design.
Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted
Off-the-shelf allogeneic CAR products are highlighted as an innovation in CAR-engineered therapies.
Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted
The CAR-engineered therapy landscape includes CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Approval Evidence
1 source1 linked approval claimfirst-pass slug car-nkt-cells
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Source:
modality diversificationsupports
The CAR-engineered therapy landscape includes CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Source:
Comparisons
Source-stated alternatives
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Source-backed strengths
presented as part of modality diversification
Source:
presented as part of modality diversification
Compared with CAR-engineered macrophages
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with CAR-macrophages
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with CAR-MΦ
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with CAR-NK
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with CAR-T
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with CAR-T cells
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with CAR-T therapy
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with chimeric antigen receptor macrophage
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with chimeric antigen receptor macrophages
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with chimeric antigen receptor natural killer cells
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with chimeric antigen receptor T cells
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with Chimeric antigen receptor T-cell therapy
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Compared with HER2-targeting CAR-M
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification.
Source:
The abstract lists CAR-T, CAR-NK, and CAR-macrophages as alternative CAR-engineered cell modalities.
Ranked Citations
- 1.